A groundbreaking global study known as KARDIA-2 has unveiled promising results for individuals struggling with high blood pressure that remains uncontrolled despite standard medications. The study involved 663 adults facing this challenge.
Enhanced Results with New Treatment
Participants received an injection of the experimental drug zilebesiran alongside their existing blood pressure medications. Findings revealed that those who received the injection experienced significantly greater reductions in blood pressure compared to those relying solely on traditional treatments.
This advancement holds significant promise, as high blood pressure affects approximately one in three adults in the UK and poses a serious risk for conditions such as heart attacks and strokes if not effectively managed.
Expert Commentary on the Treatment's Potential
Dr. Manish Saxena, Clinical Co-Director at the William Harvey Clinical Research Centre, Queen Mary University of London, and a hypertension specialist at Barts Health NHS Trust, led the UK segment of the research. He emphasized the pressing nature of hypertension as a global health issue, noting that control rates remain inadequate.
"This study highlights the safety and effectiveness of zilebesiran when combined with commonly prescribed blood pressure medications," Dr. Saxena stated. "The innovative aspect of this treatment lies in its long-lasting effects; a single injection every six months could empower millions to manage their condition more effectively."
Mechanism of Zilebesiran
Zilebesiran operates through RNA interference technology, targeting the production of angiotensinogen, a protein in the liver that plays a pivotal role in blood pressure regulation. By inhibiting this protein, the treatment allows blood vessels to relax, resulting in lower blood pressure levels. The injection is administered subcutaneously.
Future Research Directions
Researchers are advancing to a follow-up Phase 2 trial, KARDIA-3, to assess the benefits of zilebesiran for individuals with high blood pressure and existing cardiovascular conditions or those at heightened risk. Additionally, a large-scale global outcomes study is set to launch later this year to evaluate whether this treatment can diminish the likelihood of major cardiovascular events, such as strokes and cardiovascular mortality.
Funding and Research Leadership
This research was supported by Alnylam Pharmaceuticals, with Barts Health NHS Trust serving as a principal site and the leading enrollment center in Europe.
